Doctors represent hurdle for Lundbeck once again

Antidepressant Brintellix has been approved for the US market, and it should merely be a matter of time before billions starting rolling into the accounts of Lundbeck and Japanese partner Takeda. The biggest hurdle for the product is to convince doctors that the drug is as good as the two companies believe it to be, a notion that is backed by a number of clinical trials.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Here are Lundbeck’s best-performing drugs
For abonnenter
Lundbeck launches alcohol pill in Denmark
For abonnenter
Either Lundbeck or the EU Commission is lying
For abonnenter